Genetics of arrhythmogenic right ventricular cardiomyopathy--status quo and future perspectives.
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a primary myocardial disorder of unknown origin. In recent years, the disease has been recognized as a major cause of ventricular tachyarrhythmias and sudden cardiac death in young patients with apparently normal hearts. Although characteristic structural, imaging and electrocardiographic features are included in a proposed catalogue of diagnostic criteria, the correct diagnosis of ARVC often remains difficult. Much effort has been undertaken to enlarge the knowledge on pathophysiological mechanisms of the disease. The role of molecular genetics for the pathogenesis of ARVC is discussed in the following review. On the basis of linkage analyses in large families affected by ARVC, there is growing evidence for genetic alterations in ARVC, which, in the majority of chromosomal loci (seven) reported so far, follow a Mendelian autosomal-dominant pattern of inheritance with variable penetrance and polymorphic phenotype. Besides this, two autosomal-recessive forms of ARVC are known. These can be differentiated from the autosomal-dominant forms not only in terms of the mode of inheritance but also as to their specific phenotype: patients with Naxos disease exhibit characteristic hair and skin abnormalities and experience a more severe course of disease. Patients with another autosomal-recessive form display the typical but milder signs of ARVC together with opacifications of the crystalline lens. So far, two mutations in cardiac genes responsible for the development of ARVC have been reported. A homozygous two base pair deletion in the gene encoding for the cytoskeletal protein plakoglobin seems to account for the evolution of Naxos disease. The second mutation affecting the cardiac ryanodine receptor gene was found in patients with ARVC-2. Routine genetic testing of patients or relatives with a suspected diagnosis of ARVC is not available at present but may become the future gold standard with potential implications for a better understanding of the pathogenesis and management of the disease.
Paul
M
M
Universitätsklinikum Münster, Medizinische Klinik und Poliklinik C-Kardiologie und Angiologie, Albert-Schweitzer-Strasse 33, 48149 Münster, Germany. mapaul@uni-muenster.de
Schulze-Bahr
E
E
Breithardt
G
G
Wichter
T
T
D000015:Abnormalities, Multiple / Q000175:diagnosis / Q000235:genetics; D019571:Arrhythmogenic Right Ventricular Dysplasia / Q000145:classification / Q000175:diagnosis / Q000235:genetics*; D002869:Chromosome Aberrations; D002874:Chromosome Mapping; D003598:Cytoskeletal Proteins / Q000235:genetics; D004252:DNA Mutational Analysis; D016757:Death, Sudden, Cardiac / Q000209:etiology; D051180:Desmoplakins; D005799:Genes, Dominant / Q000235:genetics; D005808:Genes, Recessive / Q000235:genetics; D006801:Humans; D010641:Phenotype; D019837:Ryanodine Receptor Calcium Release Channel / Q000235:genetics; D017180:Tachycardia, Ventricular / Q000175:diagnosis / Q000235:genetics; D051185:gamma Catenin
D003598:Cytoskeletal Proteins; D051180:Desmoplakins; D019837:Ryanodine Receptor Calcium Release Channel; D051185:gamma Catenin